CLINUVEL PHARMACE
CLINUVEL PHARMACE operates in Diversified Metals & Mining.
CLINUVEL PHARMACE (UR9) - Total Assets
Latest total assets as of June 2024: €231.12 Million EUR
Based on the latest financial reports, CLINUVEL PHARMACE (UR9) holds total assets worth €231.12 Million EUR as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CLINUVEL PHARMACE - Total Assets Trend (2016–2024)
This chart illustrates how CLINUVEL PHARMACE’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
CLINUVEL PHARMACE - Asset Composition Analysis
Current Asset Composition (June 2024)
CLINUVEL PHARMACE's total assets of €231.12 Million consist of 96.1% current assets and 3.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 79.6% |
| Accounts Receivable | €25.16 Million | 10.9% |
| Inventory | €10.63 Million | 4.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €185.03K | 0.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how CLINUVEL PHARMACE's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CLINUVEL PHARMACE's current assets represent 96.1% of total assets in 2024, a decrease from 99.2% in 2016.
- Cash Position: Cash and equivalents constituted 79.6% of total assets in 2024, up from 68.8% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 10.9% of total assets.
CLINUVEL PHARMACE Competitors by Total Assets
Key competitors of CLINUVEL PHARMACE based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
2H0
F:2H0
|
Germany | €15.27 Million |
CLINUVEL PHARMACE - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - CLINUVEL PHARMACE generates 0.38x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, CLINUVEL PHARMACE generates $ 15.42 in net profit.
CLINUVEL PHARMACE - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.81 | 7.44 | 12.33 |
| Quick Ratio | 8.39 | 7.06 | 11.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €196.85 Million | € 164.12 Million | € 56.19 Million |
CLINUVEL PHARMACE - Advanced Valuation Insights
This section examines the relationship between CLINUVEL PHARMACE's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 19.3% |
| Total Assets | €231.12 Million |
| Market Capitalization | $69.22K USD |
Valuation Analysis
Below Book Valuation: The market values CLINUVEL PHARMACE's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: CLINUVEL PHARMACE's assets grew by 19.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for CLINUVEL PHARMACE (2016–2024)
The table below shows the annual total assets of CLINUVEL PHARMACE from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | €231.12 Million | +19.31% |
| 2023-06-30 | €193.71 Million | +34.57% |
| 2022-06-30 | €143.95 Million | +32.59% |
| 2021-06-30 | €108.57 Million | +33.14% |
| 2020-06-30 | €81.54 Million | +30.79% |
| 2019-06-30 | €62.35 Million | +45.31% |
| 2018-06-30 | €42.90 Million | +49.98% |
| 2017-06-30 | €28.61 Million | +42.05% |
| 2016-06-30 | €20.14 Million | -- |